EPO Market Growth

Growth of the market is driven by rise in number of treatment cycles for chemotherapy and increase in number cases including cancer, HIV, kidney diseases.

PORTLAND, OREGON, UNITED STATES, November 2, 2022 /EINPresswire.com/ -- Erythropoietin/hematopoietin is a glycoprotein hormone that triggers production of red blood cells in the bone marrow through erythropoiesis. Erythropoietin drug was developed with the objective to treat anemic conditions caused from ESRD treatments and dialysis procedures. EPO drugs have gained approvals for chemotherapy-induced anemia. Advanced application of recombinant DNA technology enables production of erythropoietin for in-vitro conditions/synthetic variants, which are referred to as recombinant human erythropoietin (rHuEPO). Currently, EPO’s, are largely used in anemic conditions induced from end stage renal disease treatment, chemotherapy, and antiretroviral treatment (ART).

The global erythropoietin drugs market size was valued at $9,243.12 million in 2020, and is projected to reach $14,414.59 million by 2028, registering a CAGR of 5.7% from 2021 to 2028.

For Right Perspective, Download Sample PDF at:

https://www.alliedmarketresearch.com/request-sample/59

Covid-19 scenario:

The outbreak of Covid-19 disrupted the workflow in the healthcare sector as the rapid spread of coronavirus forced several industries to shut down temporarily.
However, the pandemic had a positive effect on the demand for medical services including erythropoietin.
As erythropoietin is used to treat anemia and can be effective against Covid-19, which boosted its demand. Moreover, it has anti-ischemic, anti-apoptotic, and regenerative effects in several tissues such as kidney, lungs, nervous system, retina, and pancreas. Thus, it can be used to treat critically ill patients.
Rise in prevalence of anemic conditions induced from end stage renal disease treatment, chemotherapy, and antiretroviral treatment (ART). Hence, rise in number of treatment cycles for chemotherapy and increase in incidences of end stage renal diseases (dialysis) has increased demand for EPO. Side effects associated with EPO including arterial hypertension, iron deficiency, and influenza-like syndrome and longer duration of EPO treatment (4-6 weeks) restrain growth of the erythropoietin drugs market. In addition, rise in trends of commercialization for erythropoietin biosimilars, readily available reimbursements, favorable government regulations, and increase in level of awareness regarding benefits of EPO therapeutics boost growth of the erythropoietin drugs market.

Enquiry for Short-term and Long-term Impacts of COVID-19 at:

https://www.alliedmarketresearch.com/purchase-enquiry/59

Key Findings Of The Study

On the basis of product, the epoetin-alfa held largest share in the global erythropoietin drugs market in 2020.
On the basis of application, the kidney disorders held the largest erythropoietin drugs market share in 2020, and is expected to remain dominant throughout the forecast period.
By region, North America is expected to experience growth at the highest rate, during the forecast period.
(𝐈𝐧 𝐭𝐨𝐝𝐚𝐲’𝐬 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐦𝐚𝐫𝐤𝐞𝐭, 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐢𝐬 𝐚 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐬𝐭𝐞𝐩 𝐢𝐧 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐲𝐢𝐧𝐠 𝐭𝐡𝐞 𝐜𝐨𝐫𝐫𝐞𝐜𝐭 𝐭𝐚𝐫𝐠𝐞𝐭 𝐜𝐨𝐧𝐬𝐮𝐦𝐞𝐫𝐬 𝐚𝐧𝐝 𝐩𝐫𝐨𝐯𝐢𝐝𝐢𝐧𝐠 𝐜𝐮𝐬𝐭𝐨𝐦𝐢𝐬𝐞𝐝 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞𝐢𝐫 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐧𝐞𝐞𝐝𝐬. 𝐖𝐡𝐢𝐥𝐞 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐞𝐬𝐞 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬, 𝐞𝐯𝐞𝐫𝐲 𝐟𝐚𝐜𝐞𝐭 𝐚𝐧𝐝 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐩𝐫𝐨𝐛𝐥𝐞𝐦 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐝 𝐛𝐲 𝐭𝐡𝐞 𝐩𝐚𝐫𝐭𝐢𝐜𝐮𝐥𝐚𝐫 𝐬𝐞𝐜𝐭𝐨𝐫 𝐢𝐬 𝐭𝐡𝐨𝐫𝐨𝐮𝐠𝐡𝐥𝐲 𝐜𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐞𝐝. 𝐈𝐭 𝐚𝐥𝐬𝐨 𝐜𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐬 𝐧𝐮𝐦𝐞𝐫𝐨𝐮𝐬 𝐠𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭 𝐫𝐞𝐟𝐨𝐫𝐦𝐬, 𝐭𝐡𝐞 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐞𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭, 𝐜𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐛𝐞𝐡𝐚𝐯𝐢𝐨𝐮𝐫, 𝐜𝐮𝐫𝐫𝐞𝐧𝐭 𝐚𝐧𝐝 𝐟𝐮𝐭𝐮𝐫𝐞 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬, 𝐚𝐧𝐝 𝐫𝐚𝐩𝐢𝐝𝐥𝐲 𝐜𝐡𝐚𝐧𝐠𝐢𝐧𝐠 𝐭𝐞𝐜𝐡𝐧𝐢𝐜𝐚𝐥 𝐛𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐬. 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐢𝐝𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐩𝐥𝐚𝐧𝐬 𝐚𝐧𝐝 𝐩𝐨𝐥𝐢𝐜𝐢𝐞𝐬.)

VALUE PROPOSITIONS RELATED TO THE REPORT:

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
Comprehensive quantitative and qualitative insights at segment and sub-segment level
Covid 19 impact trends and perspective
Granular insights at global/regional/country level
Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
Blanket coverage on competitive landscape
Winning imperatives
Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market
On the basis of application, the kidney disorder segment dominated the market in 2020, contributing to more than two-fifths of the market. In addition, the segment is expected to manifest the highest CAGR of 6.5% during the forecast period.

Some of the Top Players in the Global Market Are:

The global erythropoietin drugs market includes an in-depth analysis of the prime market players such as Johnson & Johnson, Amgen Inc., Roche, Hospira Inc., Biocon, LG Life Sciences Ltd., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals, Ranbaxy Laboratories Ltd., and Celltrion, Inc.

Speak to our Analysts: https://www.alliedmarketresearch.com/connect-to-analyst/59

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Request for 14 days free trial: https://www.alliedmarketresearch.com/avenue/trial/starter

“We have also published few syndicated market studies in the similar area that might be of your interest.

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Submit a press release

David Correa
Allied Analytics LLP
+1 503-894-6022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.